NCT01604642已完成不适用
Role of Activin A (ActA) in the Human Cancer Cachexia
Cliniques universitaires Saint-Luc- Université Catholique de Louvain2 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2012年5月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 150
- 试验地点
- 2
- 主要终点
- Circulating Activin A level
研究概览
简要总结
The goal of the investigators study is to investigate the role of a hormone named Activin A (ActA) in the development of the skeletal muscle atrophy caused by cancer. According to the investigators hypothesis, ActA could be released by the tumor and activate a muscle atrophy gene program. To answer this question, the investigators plan first to compare circulating levels of ActA in cancer patients with and without cachexia. In a second step, the investigators would like to assess whether ActA circulating levels are predictive for the development of cachexia and short survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-year-old or older
- •Colorectal or lung cancer demonstrated by histology or cytology
- •New diagnosis or new recurrence
- •Expected survival more than 3 months
- •No previous history of other cancer in the last 5 years
- •No pregnancy or lactation
- •Signed informed consent
排除标准
- •Non-caucasian
- •Major digestive malabsorption
- •Major depression
- •Artificial nutrition
- •Height doses of steroids (>1 mg/kg hydrocortisone equivalent)
- •Hyperthyroidism
- •Other causes of malnutrition
- •Expected survival less than 3 months
- •Severely impaired walking
- •Anticoagulants or antiplatelet therapy
- •Disability or medical condition which might prevent the compliance to the protocol
- •Any conditions which may prevent the compliance to the protocol
- •Performance status ECOG > ou = 4
- •Participation to other clinical studies
研究组 & 干预措施
cachectic versus no cachectic patients
Other
blood tests, muscular biopsies
干预措施: blood tests and muscular biopsies (Other)
结局指标
主要结局
Circulating Activin A level
时间窗: 2 years
次要结局
- Muscle strength as measured by grip strength(2 years)
- Quality of life as assessed using the QLQ-C30(2 years)
- Body composition measured by bioimpedance(2 years)
- Dietary assessment measured by SNAQ score and 3-Day intake(2 years)
- Body mass index(2 years)
- Mid arm muscle circumference calculated by the triceps skinfold and the mid arm circumference(2 years)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral CancerSquamous Cell CarcinomaNCT00364715National Taiwan University Hospital
已完成
1 期
Pilot Study of Imatinib Cetuximab Combo for H & N CancerSquamous Cell Carcinoma of Head and NeckHead and Neck CancerNCT05816785University of Wisconsin, Madison15
已完成
不适用
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)Pleural Effusion, MalignantAscites, MalignantCarcinomaCarcinoma, HepatocellularCarcinoma, Renal CellCarcinoma, RenalCarcinoma, Small CellCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic DuctalCarcinoma, NeuroendocrineCarcinoma, ThymicCarcinoma, PancreaticCarcinoma BreastCarcinoma, OvarianCarcinoma BladderCarcinoma of Unknown PrimaryCarcinoma of the Head and NeckCarcinoma of the OropharynxCarcinoma of the LarynxCarcinoma of the BladderCarcinoma of EsophagusCarcinoma of the NasopharynxCarcinoma of the PenisCarcinoma of the CervixCarcinoma of the AnusCarcinoma of the VulvaCarcinoma of the AppendixCarcinoma of the Oral CavityMesotheliomaPancreatic CancerMelanomaCholangiocarcinomaNCT05461430Travera Inc72
已完成
2 期
Abiraterone Acetate in Molecular Apocrine Breast CancerBreast CancerNCT01842321UNICANCER34
已完成
1 期
Phase I Study of AT13148, a Novel AGC Kinase InhibitorAdvanced Solid TumoursNCT01585701Cancer Research UK56